Mechanistically, we uncovered for the first time that AS-IV suppresses NLRP3-mediated pyroptosis and fibrosis in PASMCs through modulating the PHD2/HIF1α signaling pathway, thus restraining PAH progression (Fig. 6). The gene discussed is NLRP3; the disease is pulmonary arterial hypertension.